ストックスクリーナーアプリを入手
0.5453
0.98%
0.0053
前日終値:
$0.54
開ける：
$0.5468
24時間の取引高:
305.75K
Relative Volume:
0.33
時価総額：
$47.61M
収益：
$2.24M
当期純損益:
$-136.67M
株価収益率:
-0.2381
EPS:
-2.29
ネットキャッシュフロー:
$-102.08M
1週間 パフォーマンス:
+11.29%
1か月 パフォーマンス:
-12.02%
6か月 パフォーマンス:
-2.63%
1年 パフォーマンス:
-66.55%
1日の値動き範囲:
$0.5323
$0.5511
1週間の範囲:
$0.48
$0.557
52週間の値動き範囲:
$0.3418
$1.83
Century Therapeutics Inc Stock (IPSC) Company Profile
名前
Century Therapeutics Inc
セクター
電話
215-981-4000
住所
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
IPSC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
0.5453 | 47.15M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-08 | 開始されました | Rodman & Renshaw | Buy |
| 2023-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-12-27 | 開始されました | Chardan Capital Markets | Buy |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-10-10 | 開始されました | Canaccord Genuity | Buy |
| 2022-05-23 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-12 | 開始されました | William Blair | Mkt Perform |
| 2021-07-13 | 開始されました | BofA Securities | Buy |
| 2021-07-13 | 開始されました | JP Morgan | Overweight |
| 2021-07-13 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Century Therapeutics Inc (IPSC) 最新ニュース
What analysts say about Century Therapeutics Inc stockStraddle and Strangle Trades & Double Or Triple Wealth - earlytimes.in
Century Therapeutics 'moving with urgency' to develop drug for Type 1 diabetes - The Business Journals
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference - Investing News Network
There is no way Century Therapeutics Inc (IPSC) can keep these numbers up - Setenews
[Form 4] Century Therapeutics, Inc. Insider Trading Activity - Stock Titan
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes - MSN
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MSN
Century Therapeutics Executive Acquires 35,000 Shares - TradingView
Chmn Pfeiffenberger Buys 35,000 ($17.3K) Of Century Therapeutics Inc [IPSC] - TradingView
Officer Cowan Files To Sell 5,462 Of Century Therapeutics Inc [IPSC] - TradingView
Research Analysts Set Expectations for IPSC FY2025 Earnings - Defense World
Century Therapeutics Inc. stock momentum explainedMarket Performance Recap & Weekly Stock Performance Updates - newser.com
What machine learning models say about Century Therapeutics Inc.2025 Fundamental Recap & Daily Technical Forecast Reports - newser.com
Century Therapeutics Executive Sells Shares to Cover Tax Obligations - TradingView
Real time pattern detection on Century Therapeutics Inc. stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
Leerink Partners Reaffirms “Market Perform” Rating for Century Therapeutics (NASDAQ:IPSC) - Defense World
Leerink Partnrs Downgrades Century Therapeutics (NASDAQ:IPSC) to Hold - Defense World
Take off with Century Therapeutics Inc (IPSC): Get ready for trading - Setenews
What technical signals suggest for Century Therapeutics Inc. stockCPI Data & Accurate Entry and Exit Point Alerts - newser.com
How Century Therapeutics Inc. stock compares to industry benchmarksMarket Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Century Therapeutics Shares Fall After Leerink Partners Downgrade - MarketScreener
IPSC Stock Downgraded by Leerink Partners: Price Target Slashed - GuruFocus
Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform, Price Target is $7 - MarketScreener
Century Therapeutics stock downgraded by Leerink Partners on lack of catalysts - Investing.com Canada
Leerink Partners Downgrades Century Therapeutics to Market Perform From Outperform - MarketScreener
What Fibonacci levels say about Century Therapeutics Inc. reboundRisk Management & Free Technical Confirmation Trade Alerts - newser.com
Analyzing drawdowns of Century Therapeutics Inc. with statistical toolsQuarterly Market Summary & AI Powered Market Entry Strategies - newser.com
Century Therapeutics Inc. stock trend outlook and recovery pathWeekly Trade Recap & High Accuracy Investment Entry Signals - newser.com
Published on: 2025-11-15 03:30:02 - newser.com
Can volume confirm reversal in Century Therapeutics Inc.2025 Trading Volume Trends & Weekly High Conviction Trade Ideas - newser.com
Century Therapeutics unveils β islet program for type 1 diabetes - BioWorld MedTech
Century Therapeutics Reports Positive Q3 2025 Earnings - TipRanks
Century Therapeutics Shrinks Costs But Net Loss Widens - Finimize
Century Therapeutics Inc. stock trendline breakdownPortfolio Growth Summary & Daily Technical Stock Forecast Reports - newser.com
Century Therapeutics unveils T1D therapy program with immune evasion tech By Investing.com - Investing.com Nigeria
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
[8-K] Century Therapeutics, Inc. Reports Material Event | IPSC SEC FilingForm 8-K - Stock Titan
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes - Investing News Network
Century Therapeutics Q3 net loss widens, despite lower costs - MarketScreener
Century Therapeutics, Inc. SEC 10-Q Report - TradingView
Century Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Century Therapeutics, Inc. Quarterly Earnings Report | IPSC SEC FilingForm 10-Q - Stock Titan
Century Therapeutics unveils T1D therapy program with immune evasion tech - Investing.com
Century Therapeutics Announces Breakthrough Allo-Evasion™ 5.0 iPSC Beta Islet Therapy for Type 1 Diabetes with Plans for IND Submission by 2026 - Quiver Quantitative
Century Therapeutics Inc (IPSC) 財務データ
収益
当期純利益
現金流量
EPS
Century Therapeutics Inc (IPSC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pfeiffenberger Brent | President and CEO |
Nov 19 '25 |
Buy |
0.50 |
35,000 |
17,328 |
3,271,453 |
0.45%
1.13%
大文字化:
|
ボリューム (24 時間):